CCSB Business Summary

Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB) operates as a specialized manufacturer of active pharmaceutical ingredients (APIs), generating revenue through the research, production, and global distribution of high-potency compounds and bulk pharmaceuticals. The company’s business model is structured around three primary segments: Biotechnology Products, which focuses on fermentation-based APIs such as immunosuppressants (e.g., Rapamycin, Tacrolimus, and Everolimus) and oncology treatments; Non-biotechnology Products, encompassing synthetic chemical APIs like muscle relaxants (Methocarbamol), expectorants (Guaifenesin), and antifungals (Fluconazole); and Contract Development and Manufacturing Organization (CDMO) services for international pharmaceutical partners. CCSB competes directly with global generic and API giants such as Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries, as well as domestic peers like Formosa Laboratories and ScinoPharm Taiwan. Within this landscape, CCSB maintains a competitive niche by leveraging its long-standing FDA-approved facilities to supply specialized, high-barrier APIs to the North American and European markets. Founded in 1964 as part of the legacy China Chemical & Pharmaceutical (CCPC) Group, CCSB is led by a management team with deep roots in the Taiwanese pharmaceutical industry. The current leadership is headed by Chairwoman Yi-Zhen Xie Wang (Wang Hsieh I-Chen), who has directed the company’s strategic expansion since 2020, and Vice-Chairman Hou-Kai Wang, who was appointed to the role in 2024. Operational execution is spearheaded by President and General Manager Chung-Hsin Huang, a veteran executive within the CCPC ecosystem. The company’s board of directors includes key representatives from the founding Wang family, such as Director Hou-Jie Wang, alongside independent directors like Chang Chih-Hsien. CCSB maintains strong institutional backing from its parent group, China Chemical & Pharmaceutical Co., Ltd. (1701.TW), and holds significant interest from global investment firms including Dimensional Fund Advisors and Cathay Life Insurance.